FOXM1 and central nervous system cancer: A trial using a polypeptide vaccine targeting LY6K, DEPDC1, KIF20A, and FOXM1 in patients with high-grade glioma showed that the vaccine was well tolerated, elicited an effective immune response, and prevented disease progression for at least 6 months [35].